Skip to main content

Table 2 Comparison of parameters related to disease activity, quality of life and concomitant therapy between C3 and C4 cohorts at the 6-month and 12-month visit

From: Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry

  6 months 12 months
C3 (n = 124) C4 (n = 491) p value C3 (n = 124) C4 (n = 491) p value
DAS28-ESR (0–10) 5.4 (4.6–6.3) 4.0 (3.5–4.5) < 0.001 3.7 (2.6–4.7) 3.7 (3.0–4.4) 0.710
TJC (28 joints) 9.0 (4.0–14.0) 3.0 (2.0–5.0) < 0.001 3.0 (1.0–7.0) 2.0 (1.0–5.0) 0.490
SJC (28 joints) 6.0 (2.0–9.5) 2.0 (1.0–4.0) < 0.001 2.0 (0.0–4.0) 2.0 (0.0–3.0) 0.498
ESR (mm/h) 28.0 (16.5–46.5) 22.0 (13.0–33.0) < 0.001 16.5 (6.5–32.0) 19.0 (11.0–30.5) 0.052
CRP (mg/l) 15.0 (7.9–28.9) 5.7 (2.5–13.7) < 0.001 4.7 (1.6–17.0) 5.0 (2.3–11.3) 0.766
SDAI (0–86) 30.2 (19.7–39.5) 13.9 (10.7–18.3) < 0.001 13.8 (8.0–20.9) 11.3 (7.7–17.4) 0.093
PTGA (0–100) 61.0 (50.0–75.0) 40.0 (26.0–50.0) < 0.001 36.0 (25.0–60.0) 33.0 (20.0–50.0) 0.044
MDGA (0–100) 58.0 (40.0–70.0) 30.0 (20.0–40.0) < 0.001 25.0 (15.0–45.0) 25.0 (15.0–40.0) 0.812
HAQ-DI (0–3) 1.5 (1.1–1.9) 1.3 (0.9–1.6) < 0.001 1.3 (0.9–1.9) 1.3 (0.9–1.6) 0.140
EQ-5D (− 0.59–1) 0.2 (0.1–0.7) 0.7 (0.5–0.7) < 0.001 0.6 (0.1–0.7) 0.7 (0.5–0.8) 0.017
Concomitant csDMARDs 98 (79.0%) 414 (84.3%) 0.159 94 (75.8%) 407 (82.9%) 0.070
Concomitant MTX 79 (63.7%) 341 (69.5%) 0.220 77 (62.1%) 332 (67.6%) 0.245
Concomitant GCs 95 (76.6%) 374 (76.2%) 0.918 92 (74.2%) 370 (75.4%) 0.789
  1. Continuous variables are described through the median (interquartile range); categorical variables are characterised by n (%)
  2. DAS28-ESR 28-joint disease activity score with ESR, TJC tender joint count, SJC swollen joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SDAI Simplified Disease Activity Index, PTGA patient general assessment of disease activity, MDGA physician general assessment of disease activity, HAQ-DI Health Assessment Questionnaire, EQ-5D EuroQol 5 Dimension for measuring the quality of life, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, MTX methotrexate, GCs glucocorticoids
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us